Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 14.53 6.60% 0.90
FATE closed up 6.6 percent on Monday, October 21, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical FATE trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup -0.07%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.07%
MACD Bullish Signal Line Cross Bullish -0.07%
NR7 Range Contraction -0.07%
Wide Bands Range Expansion -0.07%
1,2,3 Retracement Bearish Bearish Swing Setup -1.49%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.49%
Wide Bands Range Expansion -1.49%
Oversold Stochastic Weakness -1.49%
Inside Day Range Contraction 2.83%

Older signals for FATE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Orphan Diseases Cord Blood Induced Stem Cells Adult Stem Cell Lysosomal Storage Disorders
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.82
52 Week Low 11.0
Average Volume 762,668
200-Day Moving Average 17.5034
50-Day Moving Average 16.5912
20-Day Moving Average 14.8578
10-Day Moving Average 14.305
Average True Range 0.9369
ADX 39.78
+DI 9.9926
-DI 25.6115
Chandelier Exit (Long, 3 ATRs ) 15.7093
Chandelier Exit (Short, 3 ATRs ) 16.2907
Upper Bollinger Band 16.4508
Lower Bollinger Band 13.2648
Percent B (%b) 0.4
BandWidth 21.443282
MACD Line -0.7752
MACD Signal Line -0.8454
MACD Histogram 0.0702
Fundamentals Value
Market Cap 601.75 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -15.14
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.82
Resistance 3 (R3) 15.73 15.21 15.60
Resistance 2 (R2) 15.21 14.89 15.26 15.53
Resistance 1 (R1) 14.87 14.69 15.04 14.96 15.46
Pivot Point 14.36 14.36 14.44 14.40 14.36
Support 1 (S1) 14.02 14.03 14.19 14.10 13.60
Support 2 (S2) 13.50 13.83 13.54 13.53
Support 3 (S3) 13.16 13.50 13.46
Support 4 (S4) 13.24